<DOC>
	<DOCNO>NCT01420614</DOCNO>
	<brief_summary>Prospective , randomize , multi-center trial compare safety efficacy prevention net adverse clinical outcome ( NACE ) transfemoral vs. transradial approach treatment patient ST-elevation acute coronary syndrome ( STEACS ) undergo primary angioplasty</brief_summary>
	<brief_title>RadIal Versus Femoral InvEstigation ST Elevation Acute Coronary Syndrome</brief_title>
	<detailed_description>Prospective , randomize , double arm study . The study population include consecutive patient present ST-elevation Acute Coronary Syndrome candidate primary percutaneous coronary intervention , agree provide write informed consent study . Before arterial stick percutaneous access , patient randomize accord seal numbered envelope . Subsequently , arterial access obtain diagnostic/interventional procedure perform accord routine clinical practice , leave ancillary medication , choice device mean hemostasis physician 's discretion . In randomization process participate center equally stratify avoid statistical unbalance .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>1 . Subject &gt; 18 year old recent acute STelevation acute coronary syndrome ( STEACS ) require emergent coronary angiography . 2 . Patient contraindication percutaneous arterial access transfemoral route . 3 . Subject informed nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee respective clinical site . 4 . Patient treat physician agree subject comply followup evaluation . 1 . Subject 's age &lt; 18 year acute STelevation myocardial infarction ( ST elevation least 0.1 mV ≥2 extremity lead least 0.2 mV ≥2 precordial lead ) . 2 . Subject recent stroke TIA ( &lt; 4 week ) , irrespective age . 3 . Patient international normalize ratio ( INR ) &gt; 2.0 , severe bleed diathesis 4 . The patient pregnant breastfeeding . 5 . Known allergy : aspirin , clopidogrel ticlopidine , heparin , IIb/IIIa inhibitor , stainless steel , contrast agent ( adequately premedicated ) . 7.Subject currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint . 8.Prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>radial access</keyword>
	<keyword>primary angioplasty</keyword>
	<keyword>trial</keyword>
	<keyword>randomization</keyword>
	<keyword>outcome</keyword>
</DOC>